Group 1 - The company, CITIC Securities, announced that it will hold its 2025 annual performance briefing on March 27, 2026, from 9:00 to 10:00 AM via live streaming [2] - Investors can submit questions via email to the company's investor relations email address by March 24, 2026, at 23:59, or ask questions during the live event on March 27, 2026 [2] - The company will address commonly asked questions from investors during the performance briefing [2]

Group 1 - CITIC Securities reduced its stake in China Aluminum (02600) by 12 million shares at a price of HKD 12.1805 per share, totaling approximately HKD 146 million [1] - After the reduction, CITIC Securities holds approximately 264 million shares, representing a holding percentage of 6.70% [1]

Group 1 - The core point of the article is that CITIC Securities reduced its stake in China Aluminum (02600) by selling 12 million shares at a price of HKD 12.1805 per share, totaling approximately HKD 146 million [1] - After the reduction, CITIC Securities holds approximately 264 million shares, representing a holding percentage of 6.70% [1]

Group 1 - The 2026 Spring Capital Market Forum hosted by CITIC Securities took place on March 19-20, 2026, in Beijing, focusing on global macroeconomic trends and investment strategies [1] - Key topics discussed included national policy from the Two Sessions, the 14th Five-Year Plan, asset allocation, geopolitical conflicts, AI applications, real estate, REITs, and energy transition [1] - CITIC Securities emphasized the importance of high-quality development in response to external uncertainties, highlighting 2026 as a pivotal year for China's modernization goals [1] Group 2 - The capital market ecosystem is improving, with a focus on stabilizing the market and enhancing long-term investment, which is essential for high-quality development [2] - A more resilient capital market is emerging, driven by fundamental recovery and new capital inflows, transitioning from stock competition to incremental allocation [2] - Investment strategies for 2026 suggest focusing on undervalued sectors and pricing power, particularly in Chinese manufacturing [2] Group 3 - The macroeconomic outlook for China in 2026 predicts a continued recovery with an expected real GDP growth rate of around 4.9%, potentially showing a "V"-shaped growth pattern [3] - Fiscal policy is expected to remain proactive, with a deficit rate of 4% and an increase in special bonds aimed at project construction [3] - Monetary policy may allow for flexible adjustments, with expectations of 1-2 interest rate cuts and one reserve requirement ratio reduction throughout the year [3]

Group 1 - The core viewpoint of the report emphasizes that the securities industry is experiencing a recovery in valuation, driven by favorable industry conditions and potential policy reforms [4][5][34] - The report highlights that since the "924" market rally in 2024, the A-share securities index has significantly outperformed the Shanghai Composite Index, achieving a peak excess return of 35.1% [5][10] - The report identifies three main factors contributing to the underperformance of the securities sector since 2025: sustainability concerns regarding high growth expectations, the impact of refinancing on valuation, and pressures from the funding environment [15][19][24] Group 2 - The report forecasts a robust growth of approximately 10% in the securities sector's net profit for 2026, building on a high base from 2025 [34][37] - It discusses the shift in the securities business model towards wealth management and large investment banking, indicating a transition from traditional brokerage and proprietary trading to more stable revenue sources [40][41] - The report outlines the expected impact of policy reforms aimed at enhancing the role of securities firms as core intermediaries in the capital market, with a focus on increasing direct financing [46][49]

Group 1 - The core viewpoint of the article highlights that COFCO Capital (SZ 002423) announced it will accept investor research on March 19, 2026, with the company's investor relations director Zhao Yuxin participating in the reception and addressing investor inquiries [1] - Morgan Stanley's Chief Equity Strategist for China, Wang Ying, noted that since the beginning of the year, there has been a net inflow of global active funds into China, indicating a positive trend for Chinese assets amidst Middle Eastern turmoil [1]

上海证券交易所 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 上证公告（基金）【2026】560号 为促进华夏中证工程机械主题交易型开放式指数证券投资基金（以下简称华夏机械，基金代 码:515970）的市场流动性和平稳运行，根据《上海证券交易所基金自律监管规则适用指引第2号——上 市基金做市业务》等相关规定，本所同意中信证券股份有限公司自2026年03月20日起为华夏机械提供主 做市服务。 特此公告。 2026年03月19日 ...

为促进景顺长城中证全指农牧渔交易型开放式指数证券投资基金（以下简称景顺农牧，基金代 码:560210）的市场流动性和平稳运行，根据《上海证券交易所基金自律监管规则适用指引第2号——上 市基金做市业务》等相关规定，本所同意中信证券股份有限公司自2026年03月20日起为景顺农牧提供主 做市服务。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 上证公告（基金）【2026】558号 特此公告。 2026年03月19日 上海证券交易所 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 6030 自願性公告 召 開 2025 年度業績發佈會 本公告乃由中信証券股份有限公司（「本公司」）自願作出。 本公司董事會（「董事會」）謹此宣佈，本公司擬於2026年3月26日（星期四）在香港交易及 結算所有限公司披露易網站(www.hkexnews.hk)披露本公司2025年年度業績公告。 一、業績發佈會類型 為了便於廣大投資者更全面深入地了解本公司2025年度業績和經營情況，本公司擬 通過網絡直播方式召開業績發佈會，在信息披露允許的範圍內就投資者普遍關注的 問題進行交流。 二、業績發佈會召開的時間、地點 （一）會議召開時間：2026年3月27日（星期五）上午9:00–10:00 （二）網絡直播地址︰ 中文：http://roadshow.sseinfo.com（上證路演中心）； 中文+英文：https://rs.p5w.net/html/177310802035535.shtml（全景網） 三、本 ...

Core Insights - The company has reported an upward trend in the market price of experimental monkeys and has taken measures to ensure a stable supply to meet operational needs [3][4] - The growth of the company's overseas business is driven by a deepened global layout, improved business systems, and enhanced comprehensive service capabilities [4][6] - The company is focusing on building innovative technology platforms related to human cell models, AI predictions, and organoids, while also strengthening its preclinical capabilities in biopharmaceuticals [5][6] Group 1: Supply and Pricing - The market price of experimental monkeys has been increasing recently, prompting the company to diversify procurement channels and deepen cooperation with suppliers to ensure a stable supply [3][4] Group 2: Overseas Business Growth - The company's overseas business growth is attributed to a comprehensive global strategy, including the establishment of a 2,000 square meter R&D office in Boston, which has already begun generating revenue [4][6] - The company is enhancing its laboratory capabilities and business team configurations in key overseas regions, improving communication between overseas business development and domestic research teams [4][6] Group 3: Technology Platform Development - The company is advancing its innovative technology platforms, focusing on areas such as CGT, nucleic acid drugs, PROTAC, and AI, with ongoing projects in ADC preclinical research [5][6] - The company has completed numerous ADC preclinical studies and received 30 approvals, indicating a strong capability in this area [5][6] Group 4: Capacity and Talent Management - The company operates R&D laboratories in multiple locations, including Zhangjiang, Chuansha, Nanhui, and Boston, with ongoing expansion projects to enhance drug discovery and research capabilities [6][7] - The company plans to dynamically recruit talent based on business needs, focusing on technical and management personnel, while also implementing internal training and incentive mechanisms [6][7] Group 5: Project Execution Cycles - The company has three service models with varying execution cycles: product customization (1-3 months for chemical/biological services, 1-10 months for pharmacodynamics), design and development (approximately 6 months to 2.5 years), and joint efforts (typically 6 months to 1 year) [8]